期刊文献+

Plasma Kinetic Resection of Prostate Combined Terazosin for Treatment of BPH Patient with Coexisting Hypertension

Plasma Kinetic Resection of Prostate Combined Terazosin for Treatment of BPH Patient with Coexisting Hypertension
下载PDF
导出
摘要 Objective: To evaluate the efficacy and safety of terazosin and plasma kinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH) patients with coexisting hypertension. Methods: A total of 205 men who suffered from BPH with concomitant hypertension were enrolled in this study. They all received PKRP surgery and terazosin medication from one week before to 3 months after the operation. The procedures of efficacy and safety were evaluated by analysis of the changes in blood pressures, IPSS, Qmax and the drug related adverse events 4 weeks and 3 months after the operation. Results: The systolic blood pressure decreased from 161 ± 12.33 mmHg at baseline to 148 ± 7.27 mmHg four weeks (P?P?P?P?P?P? Objective: To evaluate the efficacy and safety of terazosin and plasma kinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH) patients with coexisting hypertension. Methods: A total of 205 men who suffered from BPH with concomitant hypertension were enrolled in this study. They all received PKRP surgery and terazosin medication from one week before to 3 months after the operation. The procedures of efficacy and safety were evaluated by analysis of the changes in blood pressures, IPSS, Qmax and the drug related adverse events 4 weeks and 3 months after the operation. Results: The systolic blood pressure decreased from 161 ± 12.33 mmHg at baseline to 148 ± 7.27 mmHg four weeks (P?P?P?P?P?P?P
出处 《Open Journal of Urology》 2014年第5期57-62,共6页 泌尿学期刊(英文)
关键词 Benign PROSTATIC Hyperplasia HYPERTENSION TERAZOSIN PLASMA KINETIC Vaporization of the PROSTATE Benign Prostatic Hyperplasia Hypertension Terazosin Plasma Kinetic Vaporization of the Prostate
  • 相关文献

参考文献3

二级参考文献24

  • 1吴伟江,王行环,王怀鹏,邹伟波,梁晓宇,蔡志高,钟巍巍,邹永锋,袁道彰.经尿道等离子体双极电切与经尿道普通电切对前列腺增生症的疗效比较[J].中华医学杂志,2005,85(47):3365-3367. 被引量:104
  • 2Kirby RS.The natural history of benign prostatic hyperplasia:what have we learned in the last decade? Urology,2000,56(5Suppl 1):3-6.
  • 3Girman CJ.Population based studies of the epidemiology of benign prostatic hyperplasia.Br J Urol,1998,82(Suppl 1):34-43.
  • 4Gjertson CK,Walmsley K,Kaplan SA.Benign prostatic hyperplasia:now we can begin to tailor treatment.Cleve Clin J Med,2004,71:857-865.
  • 5Lepor H.Alpha blockers for the treatment of benign prostatic hyperplasia.Rev Urol,2007,9:181-190.
  • 6O' Leafy MP.Treatment and pharmacologic management of BPH in the context of common comorbidities.Am J Manag Care,2006,12(5 Suppl):129-140.
  • 7Tanaka Y,Masumori N,Itoh N,et al.Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.J Urol,2002,167:2492-2495.
  • 8Roehrborn CG,Oesterling JE,Auerbach S,et al.The Hytrin Community Assessment Trial Study:a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostactic hyperplasia.Urology,1996,47:159-168.
  • 9Maruenda J, Bhatnagar V, Lowenthal DT. HyPertension in the elderly with coexisting benign prostatic hyperplasia. Urology, 1999, 53(Suppl 3A):7-12.
  • 10Hammarsten J, Hogstedt B, Holthuis N, et al. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 1998, 1:157-162.

共引文献197

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部